PRN: Research and Markets - Global Prostate Cancer Drugs Market Growth of 9%, 2016-2020 with AbbVie, Astellas Pharma & AstraZeneca Dominating

04/gen/2017 14:10:19 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Research and Markets - Global Prostate Cancer Drugs Market Growth of 9%, 2016-2020 with AbbVie, Astellas Pharma & AstraZeneca Dominating


DUBLIN, Jan. 4, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Prostate Cancer Drugs Market 2016-2020" report to their offering.

The report forecasts the global prostate cancer drugs market to grow at a CAGR of 9.21% during the period 2016-2020.

The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The market has been witnessing a growing popularity for targeted therapies and immunotherapies, owing to their specific mechanism of action. Immunotherapies such as vaccines, and immune checkpoint inhibitors are gaining traction in the market driven by their limited side-effects, and high efficacy.

According to the report, prostate cancer is characterized by an abnormal growth of testosterone (a hormone in the male reproductive system). Therefore, researchers have developed hormone therapies, which act by reducing the amount of testosterone in the body and stops the growth of cancer cells for several years. This development of hormone therapies and subsequent establishment of their clinical profiles have led to increased adoption among physicians.

Further, the report states that in emerging markets, the increasing costs coupled with lack of healthcare infrastructure has hindered the adoption rates of prostate cancer drugs. Most of the patients are unable to invest in these high-cost treatment options and are likely to discontinue these treatment options during the forecast period.

Key vendors:

  • AbbVie
  • Astellas Pharma
  • AstraZeneca
  • Johnson & Johnson
  • Sanofi

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Market research methodology

Part 04: Introduction

Part 05: Disease overview

Part 06: Pipeline analysis

Part 07: Market landscape

Part 08: Market segmentation by therapy

Part 09: Geographical segmentation

Part 10: Market drivers

Part 11: Impact of drivers

Part 12: Market challenges

Part 13: Impact of drivers and challenges

Part 14: Market trends

Part 15: Vendor landscape

Part 16: Key vendor analysis

Part 17: Appendix

For more information about this report visit

Media Contact:

Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


blog comments powered by Disqus è un servizio offerto da Factotum Srl